EcoDrugPlus

Nuclear Factor Kappa B Subunit 1

Ensembl ID : ENSCAFG00020002570
Gene Symbol: NFKB1
3 Cross references
205 Possible Orthologues:

Nuclear Factor Kappa B Subunit 2

Ensembl ID : ENSCAFG00020010204
Gene Symbol: NFKB2
3 Cross references
124 Possible Orthologues:

Nuclear Receptor Subfamily 1 Group H Member 2

Ensembl ID : ENSCAFG00020019507
Gene Symbol: NR1H2
3 Cross references
304 Possible Orthologues:

Nuclear Receptor Subfamily 1 Group H Member 3

Ensembl ID : ENSCAFG00020022209
Gene Symbol: NR1H3
3 Cross references
392 Possible Orthologues:

Nuclear Receptor Subfamily 1 Group H Member 4

Ensembl ID : ENSCAFG00020024269
Gene Symbol: NR1H4
3 Cross references
388 Possible Orthologues:

Nuclear Receptor Subfamily 3 Group C Member 1

Ensembl ID : ENSCAFG00020019903
Gene Symbol: NR3C1
3 Cross references
280 Possible Orthologues:

Nuclear Receptor Subfamily 3 Group C Member 2

Ensembl ID : ENSCAFG00020025992
Gene Symbol: NR3C2
3 Cross references
214 Possible Orthologues:

Nucleotide Binding Oligomerization Domain Containing 2

Ensembl ID : ENSCAFG00020001497
Gene Symbol: NOD2
3 Cross references
167 Possible Orthologues:

Opioid Receptor Delta 1

Ensembl ID : ENSCAFG00020023627
Gene Symbol: OPRD1
3 Cross references
254 Possible Orthologues:

Opioid Receptor Kappa 1

Ensembl ID : ENSCAFG00020015444
Gene Symbol: OPRK1
3 Cross references
264 Possible Orthologues:

Opioid Receptor Mu 1

Ensembl ID : ENSCAFG00020014975
Gene Symbol: OPRM1
3 Cross references
215 Possible Orthologues:

Opioid Related Nociceptin Receptor 1

Ensembl ID : ENSCAFG00020002142
Gene Symbol: OPRL1
3 Cross references
202 Possible Orthologues:

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).